[Treatment of myocardial infarct with anticoagulants, thrombolytics, inhibitors of platelet aggregation and beta receptor blockaders].
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D003374:Coumarins / Q000627:therapeutic use; D001728:Dicumarol / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D010974:Platelet Aggregation / Q000187:drug effects*; D013300:Streptokinase / Q000009:adverse effects / Q000627:therapeutic use; D013442:Sulfinpyrazone / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000925:Anticoagulants; D003374:Coumarins; D005343:Fibrinolytic Agents; D004176:Dipyridamole; D001728:Dicumarol; D006493:Heparin; D013300:Streptokinase; D001241:Aspirin; D013442:Sulfinpyrazone
Zur Therapie des Herzinfarktes mit Antikoagulantien, Thrombolytika, Thrombozytenaggregationshemmern und Beta-Rezeptorenblockern.